Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts: Gene/Protein Disease Symptom Drug Enzyme Compound   Target Concepts: Gene/Protein Disease Symptom Drug Enzyme Compound

---

Query: EC:2.6.1.2 (alanine aminotransferase)
26,722 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

Donated blood is currently screened for hepatitis B surface antigen (HBsAg), antibody to hepatitis B core antigen (anti-HBc), antibody to hepatitis C virus (anti-HCV), and alanine aminotransferase (ALT) levels to prevent posttransfusion hepatitis. A prospective study of 2368 blood donors was carried out in Guadeloupe (French West Indies) with a view to determining the risk factors associated with serologic abnormalities. Blood donors included in the study had to complete a questionnaire. Statistical analysis was performed on the data thus obtained: 571 donations (24%) were positive for at least one of the four analyzed markers. The results were that 3.2 percent were positive for HBsAg, 22 percent for anti-HBc, and 0.8 percent for anti-HCV, and 1.4 percent had ALT > or = 45 IU per L. A good correlation was found between anti-HCV and elevated ALT. Transfusion history and two socioeconomic categories (working class, military personnel) were found to be risk factors. Other risk factors were lifelong residence in Guadeloupe (with risk increasing with the number of years), birthplace and current residence in the southern part of the island, and the existence of gastrointestinal discomfort unrelated to viral hepatitis (odds ratio = 2.98). The results of this study illustrate the difficulty of implementing a preventive policy against posttransfusion hepatitis in a tropical area. The unique epidemiologic situation of Guadeloupe as regards hepatitis B virus has led to more restrictive criteria for the acceptance of blood donors.
...
PMID:Risk factors associated with hepatitis B or C markers or elevated alanine aminotransferase level among blood donors on a tropical island: the Guadeloupe experience. 141 85

Activities of arginase, alanine aminotransferase, aspartate aminotransferase and alkaline phosphatase were determined in sera obtained in a group of healthy women, women with verified carcinoma of the breast, benign mastopathy, a group of patients with carcinoma of various organs and a group of patients with acute viral hepatitis. Preoperative values of serum arginase activity in patients with breast carcinoma were up to 4-fold those found in healthy women. Sensitivity of the test was 86%. After the surgery, the activity decreased abruptly during the first week and normalised within 15-30 days. In benign diseases of the breast, the activity of arginase was normal. Serum arginase activity is raised in both benign and malignant liver diseases, however, the quotients alanine aminotransferase/arginase, aspartate aminotransferase/arginase and alkaline phosphatase/arginase differ significantly. Thus, use of alanine aminotransferase/arginase quotient implies a high degree of confidence in differentiating between increased arginase activity in mammary carcinoma (alanine aminotransferase/arginase = 0.572 +/- 0.278) and high arginase activity in hepatitis (alanine aminotransferase/arginase = 12.226 +/- 1.822).
...
PMID:Arginase, a new marker of mammary carcinoma. 142 58

The present study examined the preventive effects of green tea extract on D-galactosamine (GalN)-induced hepatic injury in rats, an animal model of viral hepatitis. A single i.p.-injection of GalN (700 mg/kg) to male Wistar rats caused fulminant hepatitis by 48 hr as assessed by marked increases in the serum aspartate aminotransferase (GOT), alanine aminotransferase (GPT) and alkaline phosphatase (ALP) activities; decreases in the serum protein and cholesterol levels and the amount of liver microsome P-450; and marked changes in organ weights. The lecithin: cholesterol acyltransferase (LCAT) activity markedly increased at 8 hr and markedly decreased at 24 hr after the GalN injection. In the experiment, animals were orally administered green tea extract at doses of 50, 100 or 200 mg/kg five times each before and after the GalN injection. Treatment with green tea extract significantly prevented the increases in the GOT, GPT and ALP activities in a dose-related manner. It also significantly prevented the decreases in serum albumin and total cholesterol, although not in a dose-related manner. A tendency to prevent the increase in LCAT activity and the decrease in liver microsome P-450 was also noted. Little effect was found on the other abnormal changes in the serum lipids and proteins and the organ weights. These results suggest that green tea may have an ameliorating effect on hepatic dysfunction.
...
PMID:[Effects of green tea extract on galactosamine-induced hepatic injury in rats]. 146 98

To evaluate the prevalence of HBV, non-A, non-B hepatitis (NANBH) and HCV, their evolution and the route of transmission, we performed a retrospective study (17 years) on 65 hemodialyzed patients (mean dialytical age 5 years, range 1-16) who developed acute viral hepatitis. Twenty-six percent of them were affected by HBV; 5 of them (29%) became chronic. Fourty-eight of 65 patients were affected by NANBH; in 1990, 42 of them were tested for antibody to HCV with the C-100 Elisa assay: 27 patients (64%) were positive. Seven of 27 patients demonstrated normal values of ALT. The evaluation of intrafamiliar transmission of HBV showed 8 sexual partners infected. In the family, no one was anti-HCV positive. In agreement with the current literature, we have observed: (1) a decrement in HBV infection; (2) that HCV is the major cause of NANBH; its rate of chronicity is over 50%; (3) that the prevalent mode of HCV transmission is the parenteral route while the sexual route seems to be negligible.
...
PMID:Retrospective study on the prevalence of B and non-A, non-B hepatitis in a dialysis unit: 17-year follow-up. 150 29

In an attempt to investigate the incidence and clinical course of type C viral hepatitis among patients with posttransfusion hepatitis, antibodies to hepatitis C virus (anti-HCV) in sera were measured from 42 prospectively followed cardiovascular surgery patients who developed hepatitis after blood transfusions. Of these, 35 (83.3%) had anti-HCV seroconversion during a 6- to 12-month follow-up period. The mean interval between blood transfusion and onset of active anti-HCV seroconversion was approximately 3 months after the first elevation of serum alanine aminotransferase levels (18.1 vs. 6.4 weeks). There was no correlation between fluctuations in serum alanine aminotransferase levels and anti-HCV titers. Of 26 patients with type C posttransfusion hepatitis who were followed greater than 1 year, 20 (76.9%) continued to have abnormal serum alanine aminotransferase levels. The results indicate that HCV is the major agent of posttransfusion hepatitis in Taiwan. Furthermore, it plays an important role in chronic hepatitis among transfused patients.
...
PMID:Antibodies to hepatitis C virus in prospectively followed patients with posttransfusion hepatitis. 164 86

An epidemiological study on hepatitis C virus infection in the populations of two villages with 5-year history of plasma donation was conducted. The prevalence rates of viral hepatitis and elevated alanine aminotransferase (ALT) level in the plasmapheretic donors of these two villages were 11.3% and 33.0%, respectively. The figures were significantly higher than those in the blood donors of these two villages, (1.5% and 10.8%, respectively), and those in the adults without blood donation living in a neighbouring village (0 and 5.0%, respectively). Of 19 patients with viral hepatitis among the plasmapheretic donors tested for anti-HCV by Chiron C-100 enzyme-linked immunoassay (EIA), 17 were positive, with positive rate of 89.5%. Of 38 patients with elevated ALT levels alone, 36 were anti-HCV positive, with the positive rate of 94.7%. Anti-HAV IgM, anti-HBc IgM, anti-CMV IgM and anti-EBV IgM were not detected in any of these 55 patients. The results demonstrated that an epidemic of hepatitis C occurred among the plasmapheretic donors in these two villages with 5-year history of plasma donation.
...
PMID:[An epidemiological study on hepatitis C among the plasmapheretic donors in two villages with a 5-year history of plasma donation]. 164 39

Seventy-seven blood samples from normal controls aged 0-8 years and 93 blood samples from children of similar ages with various viral hepatitis were investigated by measuring plasma superoxide dismutase (EC 1.15.1.1) using chemiluminescence immunoassay (CLIA). Total and Cu,Zn-SOD activities of normal controls of group 2 (1-8 years old) were significantly higher than that of normal controls of group 1 (0-1 year old) (P less than 0.01, P less than 0.01), while there were no differences of Mn-SOD activities between the two groups. Total, Cu,Zn- and Mn-SOD activities significantly increased in the acute phase (0-4 weeks after onset) and dropped to the normal levels in the restoration phase (4th week later) for 29 children with cytomegalovirus hepatitis (CMVH), in comparison with group 1. Only Mn-SOD activities were significantly increased in the acute phase (with increased ALT levels) and restoration phase (with normal ALT levels) for 18 children with hepatitis A (HA). Total and Cu,Zn-SOD activities significantly decreased and Mn-SOD activities significantly increased in both the active (with increased ALT levels) and the inactive phases (with normal ALT levels) for 36 children with chronic persistent hepatitis (CPH). Only Cu,Zn-SOD activities fell significantly in both active and inactive phases for 10 children with chronic active hepatitis (CAH).
...
PMID:Plasma superoxide dismutase measurement in children with viral hepatitis. 164 17

An epidemic of hepatitis C virus infection in plasmapheresis donors which occurred in 1985 in Gu-An county, Hebei province, was studied. A total of 3,496 persons in five villages were investigated. The prevalence rates of viral hepatitis and elevated ALT levels alone in plasmapheresis donors were 17.10% and 23.23%, respectively, which were significantly higher than these of whole blood donors and controls. 59 sera collected from plasmapheresis donors with viral hepatitis and elevated ALT levels alone were sent to the Centers for Disease Control, USA, for detection of anti-HCV with Chiron C100 (EIA). The positivity rates of anti-HCV were 97.06% and 100%, respectively, indicating that the epidemic was caused by hepatitis C virus.
...
PMID:[Epidemiological and serological study on hepatitis C virus infection in plasmapheresis donors]. 166 79

Fructus Schizandrae sinensis Baill, a traditional Chinese medicine, used as tonic and sedative, has been shown at the beginning of 70's to lower the elevated serum glutamic-pyruvic transaminase (SGPT) levels of patients suffering from chronic viral hepatitis. During past 20 years, a series of neolignans have been isolated and identified as effective principles. Pharmacological studies revealed that they increased liver protein and glycogen synthesis, antagonized liver injuries from CCl4 and thioacetamide. The mechanism of SGPT lowering was considered as a hepato-protective and membrane stabilize action, although inhibition of the activity of liver GPT may also be existed. It was found that some principles of Schizandrae have an inducing effect on hepatic microsomal drug-metabolizing enzyme system P-450, thus explained their anti-toxic, anti-carcinogenic and anti-mutagenic effects. A synthetic derivative compound of Schisandrin called DDB has most of the above mentioned actions now used widely in China as a hepato-protective drug with high effectiveness in normalizing liver functions and very low side effects. From natural Schisandrin to synthesized DDB, pointed out a successful way in the development of new drugs from natural products.
...
PMID:Bioactivity of neolignans from fructus Schizandrae. 166 71

Current notions on the role of the thymol test (TT) in the diagnosis of viral hepatitis A are discussed. Changes in TT results over the course of the disease are presented, starting from the incubation period up to the second-third week; these values are compared to those of hepatitis A specific markers. The earliest TT shifts in hepatitis A are detectable already 15-18 days before the first clinical manifestations, when this parameter surpasses the upper threshold of the range of normal values. The incubation period TT values are 6.9-8.4 U S-H, those during the 3 weeks of the acute period are 9.1-9.7 U S-H. This test earlier reacts to liver inflammation than alanine aminotransferase (a hepatic enzyme) measurement, which fact recommends TT for active early detection of hepatitis A patients in epidemic foci in collective bodies. One more TT advantage over the detection of hepatitis A specific markers in epidemic foci is that it permits the diagnosis of hepatitis whatever its etiology.
...
PMID:[Current concepts of the role of the thymol test in the laboratory diagnosis of viral hepatitis A]. 169 32


<< Previous 1 2 3 4 5 6 7 8 9 10 Next >>

---